Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Understanding the Role of 18Flurodeoxyglucose PET in Predicting Improved Survival in Locally Advanced Pancreatic Cancer.

Dholakia AS, Leal JP, Wild AT, Hacker-Prietz A, Chaudhry M, Diaz L, Wahl RL, Laheru D, Wolfgang CL, Herman JM.

Pract Radiat Oncol. 2013 Apr-Jun;3(2 Suppl 1):S26. doi: 10.1016/j.prro.2013.01.090. Epub 2013 Mar 25. No abstract available.

PMID:
24674528
2.

Predictive value of maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT in patients with locally advanced or metastatic pancreatic cancer.

Moon SY, Joo KR, So YR, Lim JU, Cha JM, Shin HP, Yang YJ.

Clin Nucl Med. 2013 Oct;38(10):778-83. doi: 10.1097/RLU.0b013e31829f8c90.

PMID:
24107806
3.

Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.

Choi M, Heilbrun LK, Venkatramanamoorthy R, Lawhorn-Crews JM, Zalupski MM, Shields AF.

Am J Clin Oncol. 2010 Jun;33(3):257-61. doi: 10.1097/COC.0b013e3181a76a0b.

4.

Positron emission tomography and stage migration in head and neck cancer.

VanderWalde NA, Salloum RG, Liu TL, Hornbrook MC, O'Keeffe Rosetti MC, Ritzwoller DP, Fishman PA, Elston Lafata J, Khandani AH, Chera BS.

JAMA Otolaryngol Head Neck Surg. 2014 Jul;140(7):654-61. doi: 10.1001/jamaoto.2014.812.

PMID:
24875939
5.

Locally advanced pancreatic cancer: the role of definitive chemoradiotherapy.

Huguet F, Mukherjee S, Javle M.

Clin Oncol (R Coll Radiol). 2014 Sep;26(9):560-8. doi: 10.1016/j.clon.2014.06.002. Epub 2014 Jul 4. Review.

PMID:
25001636
6.

Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy.

Choi HJ, Lee JW, Kang B, Song SY, Lee JD, Lee JH.

Yonsei Med J. 2014 Nov;55(6):1498-506. doi: 10.3349/ymj.2014.55.6.1498.

7.

Positive peritoneal lavage cytology is a predictor of worse survival in locally advanced pancreatic cancer.

Clark CJ, Traverso LW.

Am J Surg. 2010 May;199(5):657-62. doi: 10.1016/j.amjsurg.2010.01.021.

PMID:
20466112
8.

Definitive concurrent chemoradiotherapy in locally advanced pancreatic cancer.

Kwak YK, Lee JH, Lee MA, Chun HG, Kim DG, You YK, Hong TH, Jang HS.

Radiat Oncol J. 2014 Jun;32(2):49-56. doi: 10.3857/roj.2014.32.2.49. Epub 2014 Jun 30.

9.

Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.

Dholakia AS, Chaudhry M, Leal JP, Chang DT, Raman SP, Hacker-Prietz A, Su Z, Pai J, Oteiza KE, Griffith ME, Wahl RL, Tryggestad E, Pawlik T, Laheru DA, Wolfgang CL, Koong AC, Herman JM.

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):539-46. doi: 10.1016/j.ijrobp.2014.02.031. Epub 2014 Apr 18.

10.

Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.

Wanebo HJ, Glicksman AS, Vezeridis MP, Clark J, Tibbetts L, Koness RJ, Levy A.

Arch Surg. 2000 Jan;135(1):81-7; discussion 88.

PMID:
10636353
11.

Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial.

Davis JL, Pandalai P, Ripley RT, Langan RC, Steinberg SM, Walker M, Toomey MA, Levy E, Avital I.

Trials. 2011 May 19;12:129. doi: 10.1186/1745-6215-12-129.

12.

Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?

Konstantinidis IT, Warshaw AL, Allen JN, Blaszkowsky LS, Castillo CF, Deshpande V, Hong TS, Kwak EL, Lauwers GY, Ryan DP, Wargo JA, Lillemoe KD, Ferrone CR.

Ann Surg. 2013 Apr;257(4):731-6. doi: 10.1097/SLA.0b013e318263da2f.

PMID:
22968073
13.
14.

Clinical usefulness of ¹⁸F-fluorodeoxyglucose-positron emission tomography in patients with locally advanced pancreatic cancer planned to undergo concurrent chemoradiation therapy.

Chang JS, Choi SH, Lee Y, Kim KH, Park JY, Song SY, Cho A, Yun M, Lee JD, Seong J.

Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):126-33. doi: 10.1016/j.ijrobp.2014.05.030. Epub 2014 Jul 8.

PMID:
25015206
15.
16.

[Surgical therapy of locally advanced and primary inoperable pancreatic carcinoma after neoadjuvant preoperative radiochemotherapy].

Rau HG, Wichmann MW, Wilkowski R, Heinemann V, Sackmann M, Helmberger T, Dühmke E, Schildberg FW.

Chirurg. 2002 Feb;73(2):132-7. German.

PMID:
11974476
17.

Efficacy of gemcitabine for locally advanced pancreatic cancer: comparison with 5-fluorouracil-based chemoradiotherapy.

Tada M, Arizumi T, Nakai Y, Sasaki T, Kogure H, Togawa O, Matsubara S, Tsujino T, Hirano K, Sasahira N, Isayama H, Kawabe T, Omata M.

Chemotherapy. 2008;54(4):302-8. doi: 10.1159/000151226. Epub 2008 Aug 8. Erratum in: Chemotherapy. 2008;54(5):363. Arizumi, Masatoshi [corrected to Arizumi, Toshihiko].

PMID:
18689983
18.

Implantation of radioactive (125)I seeds improves the prognosis of locally advanced pancreatic cancer patients: A retrospective study.

Li YF, Liu ZQ, Zhang YS, Dong LM, Wang CY, Gou SM, Wu HS.

J Huazhong Univ Sci Technolog Med Sci. 2016 Apr;36(2):205-10. doi: 10.1007/s11596-016-1567-x. Epub 2016 Apr 13.

PMID:
27072963
19.
20.

Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.

Ishii H, Furuse J, Boku N, Okusaka T, Ikeda M, Ohkawa S, Fukutomi A, Hamamoto Y, Nakamura K, Fukuda H; JCOG Gastrointestinal Oncology Study Group.

Jpn J Clin Oncol. 2010 Jun;40(6):573-9. doi: 10.1093/jjco/hyq011. Epub 2010 Feb 25.

Items per page

Supplemental Content

Write to the Help Desk